AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25439094 — intervention group
Group type: COMPARATOR
Intervention: No cognitive dysfunction
Number of subjects: 613
Study 25439363 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide-formoterol combination (BFC)
Number of subjects: 3043
Study 25439363 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone-salmeterol combination (FSC)
Number of subjects: 3043
Study 25439371 — intervention group
Group type: EXPERIMENTAL
Intervention: Atopy (serum specific IgE positivity)
Number of subjects: 14849
Study 25439577 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin in addition to hypothermia
Number of subjects: 24
Study 25439612 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 25439689 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide plus rituximab
Number of subjects: 110
Study 25439689 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide plus rituximab in follicular lymphoma
Number of subjects: 110
Study 25439689 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide plus rituximab in marginal zone lymphoma
Number of subjects: 110
Study 25439689 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide plus rituximab in small lymphocytic lymphoma
Number of subjects: 110
Study 25439689 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 110
Study 25439769 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine cervical mediastinoscopy before lung resection
Number of subjects: 90
Study 25439769 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical resection after mediastinoscopy
Number of subjects: 90
Study 25439769 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall evaluation of nodal upstaging
Number of subjects: 90
Study 25439771 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular aortic repair using Valiant Captivia
Number of subjects: 50
Study 25439791 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-contrast-enhanced coronary calcium scanning by CT
Number of subjects: 7500
Study 25439791 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery CT angiography
Number of subjects: 7500
Study 25439791 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole genome sequencing
Number of subjects: 7500
Study 25439791 — intervention group
Group type: EXPERIMENTAL
Intervention: DNA methylation
Number of subjects: 7500
Study 25439791 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole blood-based transcriptome sequencing
Number of subjects: 7500
Study 25439791 — intervention group
Group type: EXPERIMENTAL
Intervention: Unbiased proteomics based on mass spectrometry
Number of subjects: 7500
Study 25439791 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolomics and lipidomics on a mass spectrometry platform
Number of subjects: 7500
Study 25439791 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary phenotype analysis
Number of subjects: 7500
Study 25439791 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional phenotypic analyses
Number of subjects: 7500
Study 25439846 — intervention group
Group type: EXPERIMENTAL
Intervention: Uterus transplantation (UTx) with tacrolimus and mychophenolate mofetil (MMF) for 6 months, followed by MMF withdrawal.
Number of subjects: 7
Study 25441108 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib 50 mg b.i.d. (n = 4)
Number of subjects: 27
Study 25441108 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib 100 mg b.i.d. (n = 5)
Number of subjects: 27
Study 25441108 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib 200 mg b.i.d. (n = 18)
Number of subjects: 27
Study 25441108 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cohort (n = 27)
Number of subjects: 27
Study 25441562 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic shoulder stabilization
Number of subjects: 36
Study 25441562 — intervention group
Group type: COMPARATOR
Intervention: Open shoulder stabilization
Number of subjects: 36
Study 25441562 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 36
Study 25441679 — intervention group
Group type: EXPERIMENTAL
Intervention: Kidney function characterized by estimated glomerular filtration rate (eGFR) using the abbreviated Modification of Diet in Renal Disease formula.
Number of subjects: 97
Study 25441679 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariable regression adjusting for age, race, log tumor necrosis factor α, hypertension, dyslipidemia, and diabetes.
Number of subjects: 97
Study 25441726 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical control suggested in the guidelines
Number of subjects: 93
Study 25441734 — intervention group
Group type: EXPERIMENTAL
Intervention: Danish Bone Society (DBS-DK)
Number of subjects: 88
Study 25441734 — intervention group
Group type: EXPERIMENTAL
Intervention: UK National Osteoporosis Guideline Group (NOGG-UK)
Number of subjects: 88
Study 25441734 — intervention group
Group type: EXPERIMENTAL
Intervention: US National Osteoporosis Foundation (NOF-US)
Number of subjects: 88
Study 25441734 — intervention group
Group type: EXPERIMENTAL
Intervention: Garvan Fracture Risk Calculator
Number of subjects: 88
Study 25441734 — intervention group
Group type: EXPERIMENTAL
Intervention: Q-fracture 2012
Number of subjects: 88
Study 25441734 — intervention group
Group type: COMPARATOR
Intervention: Agreement among guidelines
Number of subjects: 88
Study 25441735 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT)
Number of subjects: 41
Study 25441735 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP)
Number of subjects: 41
Study 25441735 — intervention group
Group type: COMPARATOR
Intervention: Control group (no infection)
Number of subjects: 41
Study 25441924 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive screening methods (ADA risk test and body composition measures)
Number of subjects: 0
Study 25441924 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive screening methods
Number of subjects: 0
Study 25442036 — intervention group
Group type: EXPERIMENTAL
Intervention: Contura multilumen balloon (CMLB) breast brachytherapy catheter delivering accelerated partial breast irradiation (APBI) with a total dose of 34 Gy in 10 fractions, delivered twice daily.
Number of subjects: 342
Study 25442036 — intervention group
Group type: EXPERIMENTAL
Intervention: Contura multilumen balloon (CMLB) breast brachytherapy catheter at high-volume centers.
Number of subjects: 342
Study 25442039 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy (SBRT) with a dose of 42 Gy/3 fractions for targets ≥5 cm and 26 Gy/1 fraction for targets <5 cm.
Number of subjects: 20
Study 25442084 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic temporary esophageal stenting after single-stage complete Barrett's excision (CBE)
Number of subjects: 14
Study 25442084 — intervention group
Group type: COMPARATOR
Intervention: Single-stage complete Barrett's excision (CBE)
Number of subjects: 14
Study 25442074 — intervention group
Group type: EXPERIMENTAL
Intervention: Genomic microarray analysis using formalin-fixed paraffin-embedded tissue (FFPET)
Number of subjects: 44
Study 25442074 — intervention group
Group type: COMPARATOR
Intervention: Genomic microarray analysis using frozen tissue (FZT)
Number of subjects: 44
Study 25442074 — intervention group
Group type: COMPARATOR
Intervention: CEP3 FISH analysis
Number of subjects: 44
Study 25442074 — intervention group
Group type: EXPERIMENTAL
Intervention: CGH detection of -3, +8q, -8p on FFPET and FZT
Number of subjects: 44
Study 25442689 — intervention group
Group type: EXPERIMENTAL
Intervention: Latrine promotion and construction
Number of subjects: 4586
Study 25442689 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 4586
Study 25442806 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous metronidazole (MNZ) combined with ceftriaxone (CTRX) at doses of 500 mg 3 or 4 times a day/1 or 2 g twice a day
Number of subjects: 38
Study 25442806 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous metronidazole (MNZ) combined with ceftriaxone (CTRX)
Number of subjects: 38
Study 25444147 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 100 mg/day
Number of subjects: 278
Study 25444147 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 278
Study 25444253 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 581
Study 25444253 — intervention group
Group type: COMPARATOR
Intervention: No Doxycycline
Number of subjects: 581
Study 25444307 — intervention group
Group type: EXPERIMENTAL
Intervention: Nosocomial influenza-like illness (noso-ILI)
Number of subjects: 21519
Study 25444307 — intervention group
Group type: COMPARATOR
Intervention: Other wards
Number of subjects: 21519
Study 25444527 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe (EZE)
Number of subjects: 8
Study 25444566 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate (PP)
Number of subjects: 593
Study 25444722 — intervention group
Group type: EXPERIMENTAL
Intervention: CD20-specific CAR coupled with CD137 and the CD3ζ moiety
Number of subjects: 7
Study 25444781 — intervention group
Group type: EXPERIMENTAL
Intervention: AS02B
Number of subjects: 93
Study 25444781 — intervention group
Group type: EXPERIMENTAL
Intervention: AS02V
Number of subjects: 93
Study 25444781 — intervention group
Group type: EXPERIMENTAL
Intervention: AS01B
Number of subjects: 93
Study 25444781 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 93
Study 25445775 — intervention group
Group type: EXPERIMENTAL
Intervention: Previously named object pictures
Number of subjects: 0
Study 25445775 — intervention group
Group type: COMPARATOR
Intervention: New object pictures
Number of subjects: 0
Study 25445775 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral experiment with previously named pictures as primes
Number of subjects: 0
Study 25446240 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant-retained FDPs
Number of subjects: 27
Study 25446240 — intervention group
Group type: COMPARATOR
Intervention: Tooth-retained FDPs
Number of subjects: 27
Study 25446831 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of A/Netherlands/219/03 (H7N7) pLAIV (10^7.5 TCID50 intranasally)
Number of subjects: 0
Study 25446831 — intervention group
Group type: COMPARATOR
Intervention: One dose of A/chicken/British Columbia/CN-6/04 (H7N3) pLAIV (10^7.5 TCID50 intranasally)
Number of subjects: 0
Study 25446831 — intervention group
Group type: EXPERIMENTAL
Intervention: One 45 μg dose of H7N7 pIIV (intramuscularly)
Number of subjects: 0
Study 25447610 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 22576
Study 25447728 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV DNA detection
Number of subjects: 443
Study 25447728 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV type distribution
Number of subjects: 443
Study 25447728 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-related prevalence
Number of subjects: 443
Study 25447728 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall HPV prevalence
Number of subjects: 443
Study 25448409 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 months internet-based guided self-help (INT-GSH)
Number of subjects: 156
Study 25448409 — intervention group
Group type: COMPARATOR
Intervention: Conventional guided bibliotherapy (BIB-GSH)
Number of subjects: 156
Study 25448923 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucosal impedance (MI) measurement in patients with GERD (erosive esophagitis or nonerosive but pH-abnormal GERD)
Number of subjects: 348
Study 25448923 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucosal impedance (MI) measurement in patients with eosinophilic esophagitis
Number of subjects: 348
Study 25448923 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucosal impedance (MI) measurement before and after acid suppressive therapy
Number of subjects: 348
Study 25448923 — intervention group
Group type: COMPARATOR
Intervention: Mucosal impedance (MI) measurement compared to wireless pH monitoring
Number of subjects: 348
Study 25449006 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-stage repair (n = 27)
Number of subjects: 87
Study 25449006 — intervention group
Group type: COMPARATOR
Intervention: Single-stage repair (n = 32)
Number of subjects: 87
Study 25449006 — intervention group
Group type: COMPARATOR
Intervention: Unintentionally staged repair (n = 28)
Number of subjects: 87
Study 25449219 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational age ≤25 weeks
Number of subjects: 1239
Study 25449219 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational age 26 or 27 weeks
Number of subjects: 1239
Study 25449219 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational age 28 or 29 weeks
Number of subjects: 1239
Study 25449219 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational age ≥30 weeks
Number of subjects: 1239
Study 25449219 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants with GA ≤27 weeks
Number of subjects: 1239
Study 25449219 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous exam findings, GA, and PMA
Number of subjects: 1239
Study 25449569 — intervention group
Group type: COMPARATOR
Intervention: ICRA
Number of subjects: 461
Study 25449569 — intervention group
Group type: EXPERIMENTAL
Intervention: ICRA + ROMA
Number of subjects: 461
Study 25449569 — intervention group
Group type: EXPERIMENTAL
Intervention: ROMA + ICRA (for all malignancies)
Number of subjects: 461
Study 25450031 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg daily and docetaxel 60 mg/m(2)
Number of subjects: 15
Study 25450031 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus alone
Number of subjects: 15
Study 25450031 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus with docetaxel
Number of subjects: 15
Study 25450151 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node (SLN) biopsy after cervical dual injection (technetium and patent blue) and systematic pelvic node dissection
Number of subjects: 125
Study 25450151 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node (SLN) biopsy
Number of subjects: 125
Study 25450151 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant therapy
Number of subjects: 125
Study 25450151 — intervention group
Group type: EXPERIMENTAL
Intervention: External beam radiotherapy (EBRT)
Number of subjects: 125
Study 25450151 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 125
Study 25451051 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous voriconazole 9 mg/kg followed by 8 mg/kg every 12 hours, and oral voriconazole 9 mg/kg (max 350 mg) every 12 hours for patients <50 kg or 6 mg/kg followed by 4 mg/kg every 12 hours and 200 mg oral voriconazole every 12 hours for patients ≥50 kg
Number of subjects: 21
Study 25451053 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-450 coadministered with ritonavir
Number of subjects: 0
Study 25451053 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-450 at highest dose
Number of subjects: 0
Study 25451055 — intervention group
Group type: EXPERIMENTAL
Intervention: Ombitasvir 5 mg
Number of subjects: 12
Study 25451055 — intervention group
Group type: EXPERIMENTAL
Intervention: Ombitasvir 25 mg
Number of subjects: 12
Study 25451055 — intervention group
Group type: EXPERIMENTAL
Intervention: Ombitasvir 50 mg
Number of subjects: 12
Study 25451055 — intervention group
Group type: EXPERIMENTAL
Intervention: Ombitasvir 200 mg
Number of subjects: 12
Study 25451055 — intervention group
Group type: EXPERIMENTAL
Intervention: Ombitasvir (all doses)
Number of subjects: 12
Study 25451055 — intervention group
Group type: EXPERIMENTAL
Intervention: Ombitasvir (doses higher than 5 mg)
Number of subjects: 12
Study 25451401 — intervention group
Group type: EXPERIMENTAL
Intervention: Unique symptom profiles identified in the STAR*D study
Number of subjects: 3703
Study 25451401 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall depression severity control
Number of subjects: 3703
Study 25452198 — intervention group
Group type: EXPERIMENTAL
Intervention: OneShot Renal Denervation System
Number of subjects: 50
Study 25452435 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 1 diabetes
Number of subjects: 5566
Study 25452435 — intervention group
Group type: COMPARATOR
Intervention: Control (women without diabetes)
Number of subjects: 5566
Study 25452445 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel node biopsy (SNB) with mandatory immunohistochemistry (IHC)
Number of subjects: 153
Study 25452591 — intervention group
Group type: EXPERIMENTAL
Intervention: High vaginal loads of Atopobium vaginae and Gardnerella vaginalis
Number of subjects: 813
Study 25452591 — intervention group
Group type: EXPERIMENTAL
Intervention: High vaginal load of Atopobium vaginae
Number of subjects: 813
Study 25452591 — intervention group
Group type: EXPERIMENTAL
Intervention: A. vaginae levels ≥10(8) copies/mL
Number of subjects: 813
Study 25452614 — intervention group
Group type: EXPERIMENTAL
Intervention: aNK-DLI (IL-15/4-1BBL-activated NK cells)
Number of subjects: 9
Study 25452708 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH antagonist 0.25 mg
Number of subjects: 50
Study 25452708 — intervention group
Group type: EXPERIMENTAL
Intervention: recLH (Luveris, 150 IU/day) added to 'over-suppressed' patients
Number of subjects: 50
Study 25452859 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinopathy
Number of subjects: 4038
Study 25452859 — intervention group
Group type: COMPARATOR
Intervention: No retinopathy
Number of subjects: 4038
Study 25452867 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 μg vitamin D3
Number of subjects: 251
Study 25452867 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 μg vitamin D3
Number of subjects: 251
Study 25452867 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 251
Study 25452874 — intervention group
Group type: EXPERIMENTAL
Intervention: Medtronic Sentrino continuous glucose management (CGM) system
Number of subjects: 21
Study 25453541 — intervention group
Group type: EXPERIMENTAL
Intervention: High glycemic load diet
Number of subjects: 306
Study 25453541 — intervention group
Group type: EXPERIMENTAL
Intervention: High glycemic index diet (in participants with BMI ≥ 25)
Number of subjects: 306
Study 25453541 — intervention group
Group type: EXPERIMENTAL
Intervention: High glycemic index diet (in participants with BMI < 25)
Number of subjects: 306
Study 25453541 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted for BMI, alcohol consumption, and total energy intake
Number of subjects: 306
Study 25453718 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter pulmonary valve implantation
Number of subjects: 64
Study 25453876 — intervention group
Group type: EXPERIMENTAL
Intervention: 25-cm Gore Viabahn Endoprosthesis
Number of subjects: 71
Study 25453890 — intervention group
Group type: EXPERIMENTAL
Intervention: PTFE-covered stent-grafts
Number of subjects: 118
Study 25453890 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyester covered stent-grafts
Number of subjects: 118
Study 25454012 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma identification and medication administration forms
Number of subjects: 0
Study 25455511 — intervention group
Group type: EXPERIMENTAL
Intervention: Steady-State Plasma Glucose (SSPG)
Number of subjects: 39
Study 25455511 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Mass Index (BMI)
Number of subjects: 39
Study 25455511 — intervention group
Group type: EXPERIMENTAL
Intervention: Steady-State Plasma Glucose (SSPG) in adults <45 years
Number of subjects: 39
Study 25455511 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Mass Index (BMI) in adults ≥45 years
Number of subjects: 39
Study 25456091 — intervention group
Group type: EXPERIMENTAL
Intervention: Training plus organizational linkage intervention
Number of subjects: 20
Study 25456091 — intervention group
Group type: COMPARATOR
Intervention: Training alone
Number of subjects: 20
Study 25456362 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacomitinib (45 mg or 30 mg orally once daily) until progressive disease, unacceptable toxicity, or patient withdrawal
Number of subjects: 89
Study 25456362 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacomitinib (45 mg or 30 mg orally once daily)
Number of subjects: 89
Study 25456368 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (100 mg/m(2) intravenously every 3 weeks) plus trastuzumab (8 mg/kg intravenously every 3 weeks then 6 mg/kg intravenously every 3 weeks for the second course)
Number of subjects: 142
Study 25456368 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (100 mg/m(2) intravenously every 3 weeks) plus trastuzumab (6 mg/kg intravenously every 3 weeks) plus bevacizumab (15 mg/kg intravenously every 3 weeks; group A)
Number of subjects: 142
Study 25456368 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel (100 mg/m(2) intravenously every 3 weeks) plus trastuzumab (6 mg/kg intravenously every 3 weeks; group B)
Number of subjects: 142
Study 25456369 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ixazomib (2.97 mg/m2) plus lenalidomide 25 mg and dexamethasone 40 mg for up to 12 cycles, followed by maintenance therapy with ixazomib alone.
Number of subjects: 65
Study 25456369 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ixazomib (3.95 mg/m2) in phase 1.
Number of subjects: 65
Study 25456369 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ixazomib (2.23 mg/m2, converted to 4.0 mg fixed dose) in phase 2.
Number of subjects: 65
Study 25456414 — intervention group
Group type: EXPERIMENTAL
Intervention: Cobalt-chromium thin strut bare metal stent with passive coating
Number of subjects: 1016
Study 25456692 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 0
Study 25456692 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 0
Study 25456759 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR) with SAPIEN 3 valve
Number of subjects: 150
Study 25456759 — intervention group
Group type: COMPARATOR
Intervention: Nontransfemoral alternative access
Number of subjects: 150
Study 25457053 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting bioresorbable scaffold (BRS) implantation
Number of subjects: 40
Study 25457458 — intervention group
Group type: EXPERIMENTAL
Intervention: Multibranched endovascular aneurysm repair
Number of subjects: 116
Study 25457458 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline glomerular filtration rate <30 mL/min/1.73 m(2)
Number of subjects: 116
Study 25457458 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoroscopy time >190 minutes
Number of subjects: 116